These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2369568)

  • 41. Long-term cyclosporine in the management of psoriasis.
    Fry L; Griffiths CE; Powles AV; Baker BS; Valdimarsson H
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):23-5. PubMed ID: 3381276
    [No Abstract]   [Full Text] [Related]  

  • 42. Safety and tolerability of cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome. Collaborative Study Group of Sandimmun in Nephrotic Syndrome.
    Clin Nephrol; 1991; 35 Suppl 1():S48-60. PubMed ID: 1860268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cutaneous malignancy related to cyclosporin A therapy.
    Green C; Hawk JL
    Clin Exp Dermatol; 1993 Jan; 18(1):30-1. PubMed ID: 8440049
    [No Abstract]   [Full Text] [Related]  

  • 44. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T; Furukawa F; Iwatsuki K; Matsue H; Shimada S; Takigawa M; Tokura Y
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis.
    Berg KJ; Førre O; Djøseland O; Mikkelsen M; Narverud J; Rugstad HE
    Clin Nephrol; 1989 May; 31(5):232-8. PubMed ID: 2661065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between lymphocyte cyclosporin sensitivity and clinical progress of psoriasis.
    Umezawa Y; Oh-i T; Koga M
    J Dermatol Sci; 2001 Jun; 26(2):94-9. PubMed ID: 11378324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer induction by immunosuppression in psoriasis after heavy PUVA treatment.
    Molin L; Larkö O
    Acta Derm Venereol; 1997 Sep; 77(5):402. PubMed ID: 9298142
    [No Abstract]   [Full Text] [Related]  

  • 49. Cyclosporin A treatment of severe steroid resistant nephrotic syndrome in adults.
    Nyrop M; Olgaard K
    J Intern Med; 1990 Jan; 227(1):65-8. PubMed ID: 2299300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term treatment of severe psoriasis with low-dose cyclosporin: (2.5 mg/kg/day to 5 mg/kg/day).
    Frappaz A; Haftek H; Thivolet J
    Acta Derm Venereol Suppl (Stockh); 1989; 146():147. PubMed ID: 2692369
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
    Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O
    J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of cyclosporin A (CyA) in psoriasis: an overview of dose/response, indications, contraindications and side-effects.
    Zachariae H; Steen Olsen T
    Clin Nephrol; 1995 Mar; 43(3):154-8. PubMed ID: 7774070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clearance of psoriasis with low dose cyclosporin.
    Griffiths CE; Powles AV; Leonard JN; Fry L; Baker BS; Valdimarsson H
    Br Med J (Clin Res Ed); 1986 Sep; 293(6549):731-2. PubMed ID: 3094629
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.
    Witkamp L; Zonneveld IM; Jung EG; Schopf RE; Christophers E; Grossman R; Meffert H; Belaich S; Mahrle G; Van Joost T
    Br J Dermatol; 1995 Jul; 133(1):95-103. PubMed ID: 7669649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis.
    Brown AL; Wilkinson R; Thomas TH; Levell N; Munro C; Marks J; Goodship TH
    Br J Dermatol; 1993 May; 128(5):550-5. PubMed ID: 8504048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term use of cyclosporin in liver grafting.
    Williams R; Blackburn A; Neuberger J; Calne RY
    Q J Med; 1985 Dec; 57(224):897-905. PubMed ID: 3912795
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.
    Sinha MD; MacLeod R; Rigby E; Clark AG
    Nephrol Dial Transplant; 2006 Jul; 21(7):1848-54. PubMed ID: 16311257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.
    Stern RS; Liebman EJ; Väkevä L
    J Natl Cancer Inst; 1998 Sep; 90(17):1278-84. PubMed ID: 9731734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis.
    Edwards BD; Chalmers RJ; O'Driscoll JB; Mitchell DM; Smith RJ; Lawson RS; Testa HJ; Ballardie FW
    Clin Nephrol; 1994 Jun; 41(6):350-6. PubMed ID: 8076438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
    Schopf RE; Hultsch T; Lotz J; Bräutigam M
    J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.